Advancing Hepatitis C Elimination: A Coordinated National Approach


Advancing Hepatitis C Elimination: A Coordinated National Approach

December 5, 2023 — 12:30PM–4:00PM

Hybrid - National Press Club, Washington D.C.

Event Graphics Including Name Time and Date of Event


Sessions 1, 2, & 3

Sessions 4 & 5

The final copy of the Duke-Margolis policy brief, "Advancing Hepatitis C Elimination: A Coordinated Public Health and Health Care Strategy" is now available.

Background and Meeting Objectives

Chronic hepatitis C infection continues to cause significant morbidity and mortality and is a leading cause of liver cancer and liver transplantation in the US, despite the availability of curative therapies. The Biden Administration has proposed a national program for hepatitis C elimination that prioritizes the development of point of care diagnostics, broad access to curative direct-acting antiviral (DAA) therapy, and comprehensive public health efforts to engage, inform, identify, and treat individuals with hepatitis C.1 The Duke-Margolis Center for Health Policy has developed a strategic framework and implementation pathway that describes coordinated, complimentary activities to be carried out by actors at the local, state, and national level to advance hepatitis C elimination across impacted populations. The Duke-Margolis work on this framework has focused on leveraging recent experiences in public health and health care delivery transformation, including building test-to-treat programs in community based primary care models; effective COVID-19 management resulting from improved public health analytics; and provider payment reforms that promote continuity and accountability of care to ensure effectiveness and long-term sustainability of an elimination program and maximum impact of a federal investment.

The Duke-Margolis Center for Health Policy is hosting a public meeting to introduce and present key details from a soon to be published report, including the strategic framework outlining core areas for improvement across the hepatitis C care cascade, the implementation pathway for reaching each of the key populations, and supportive evidence and lessons learned from past and ongoing public health and healthcare delivery transformation programs.


Acknowledgement of Funding

Funding for this project was made possible in part by Arnold Ventures LLC. The views expressed in events, written materials, or publications and by participants do not necessarily reflect the official views not endorsement by Arnold Ventures LLC.

Duke-Margolis Project Team


Beena Bhuiyan Khan, MSc

Research Director for Payment and Coverage Policy

Christina Bush Headshot

Christina Bush, MPH

Policy Analyst

Hannah Graunke Headshot

Hannah Graunke, MPP

Senior Policy Analyst


Marianne Hamilton Lopez, PhD, MPA

Senior Research Director, Biomedical Innovation
Faculty Director of the Duke-Margolis Postdoctoral Associates & Affiliated Fellows Program
Adjunct Associate Professor
Senior Team Member
Margolis Core Faculty

Mark McClellan

Mark McClellan, MD, PhD

Director of the Duke-Margolis Institute for Health Policy
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty

More information about our project, Advancing Hepatitis C Elimination, including prior publications, is available on our project webpage.